Regenerative medicine is the set of techniques that repair, replace, or regrow damaged cells, tissues, and organs instead of just managing symptoms. It includes stem cell transplants, lab-grown skin, gene-edited blood cells, and a few simpler tools like platelet-rich plasma. A handful of these treatments are proven and approved. Many more are experimental, and a large number of clinics sell them anyway.
This list separates the three groups, with sources where a claim needs one.
TLDR – Regenerative medicine is an umbrella term. Stem cell therapy is one part of it. – The oldest and most successful example is the bone marrow transplant, first done in 1956. – The FDA has approved a short list of cell and gene therapies, mostly for blood disorders, burns, and cartilage damage. – It cannot yet fix stroke, heart failure, Alzheimer’s, or grow most whole organs. – Unapproved stem cell clinics have caused real harm, including blindness.
Contents
- What regenerative medicine is and where it started
- The main tools
- Approved versus experimental
- Scale and limits
- Safety, cost, and red flags
What regenerative medicine is and where it started
1. Regenerative medicine is an umbrella, not a single treatment. It covers cell therapy, tissue engineering, gene therapy, and biomaterials. That’s the answer to the common “regenerative medicine vs stem cell therapy” question: stem cell therapy is one branch, and plenty of regenerative approaches use no stem cells at all.
2. The first regenerative treatment was a bone marrow transplant. E. Donnall Thomas performed the first successful one in 1956, between identical twins, and shared the 1990 Nobel Prize in Medicine for the work. Transplanted blood-forming stem cells rebuild an entire blood and immune system. Seventy years later, nothing else in the field has a longer record.
3. Your body already regenerates, just unevenly. The liver can regrow from a small remnant to near full size within months, which is why living donors can give part of theirs. Heart muscle is the opposite. A study in Science used carbon-14 dating to show that heart muscle cells renew at roughly 1% a year at age 25 and about 0.45% a year at 75. Zebrafish and salamanders regrow heart tissue and limbs. Humans mostly scar.
The main tools
4. Adult stem cells do most of the proven work. “Adult” just means non-embryonic. Blood-forming stem cells from bone marrow, circulating blood, or donated umbilical cord blood are the best-established type, and they treat leukemias, lymphomas, and inherited blood disorders.
5. Induced pluripotent stem cells (iPSCs) turn skin cells into almost anything. Shinya Yamanaka’s team reprogrammed mouse cells in 2006 and human cells in 2007, and he shared the 2012 Nobel Prize with John Gurdon. The appeal is obvious: a patient’s own cells, converted to heart, nerve, or retinal cells, with less risk of immune rejection.
6. The embryonic-cell objection mostly doesn’t apply to today’s treatments. Human embryonic stem cells exist and are studied, but the cell-based products on the FDA’s approved list come from other sources: donated cord blood, adult bone marrow, donor pancreases, or the patient’s own cells. If your hesitation about “stem cell therapy” is about embryos, the approved options aren’t built on them. If the embryo question is the sticking point, 7 myths and misconceptions about cloning separates what current science supports from what gets repeated.
7. Tissue engineering builds structures, not just cell suspensions. The basic recipe is cells seeded onto a scaffold, then grown into tissue. Anthony Atala’s team implanted lab-grown bladders in young patients starting in 1999. Flat or hollow structures like skin, cartilage, and bladders are feasible. Dense, blood-hungry organs are not.
8. Gene therapy now counts as regenerative medicine. In December 2023 the FDA approved Casgevy, the first therapy based on CRISPR gene editing, for sickle cell disease. Doctors take the patient’s own blood stem cells, edit them in a lab, and infuse them back. The goal is a new, working blood system.
9. Platelet-rich plasma (PRP) is the simplest tool and the least settled. A clinic draws your blood, spins out the platelets, and injects them into an injured joint or tendon. It’s cheap and low-risk because the material is yours. The evidence is mixed: some trials show benefit for knee osteoarthritis, others show little over placebo, and results vary by injury and preparation method. It’s also not a stem cell treatment, whatever the clinic’s brochure suggests.
Approved versus experimental
10. The FDA’s approved list is short. The agency publishes its approved cellular and gene therapy products in one place. Several entries are cord blood products, the first of which won approval in 2011, and they’re used for blood and immune system disorders. Compare that to the thousands of clinics advertising stem cell injections.
11. The first approved mesenchymal stem cell therapy arrived in late 2024. Ryoncil was approved for children with steroid-refractory acute graft-versus-host disease. Mesenchymal cells are the type most clinics claim to inject for knees, backs, and skin. Until that approval, none had FDA clearance for any use, and the one approval covers a serious pediatric transplant complication, not joint pain.
12. Several approved products are engineered tissue. MACI (2016) uses a patient’s own cartilage cells to repair knee defects. StrataGraft (2021) treats deep burns. Lantidra (2023) delivers donor pancreatic islet cells to some adults with type 1 diabetes. Cultured skin grafts for severe burns go back to the early 1980s, which makes skin the original lab-grown tissue.
13. iPSC-derived therapies are still in trials. In 2014, a team in Kobe, Japan, led by Masayo Takahashi, implanted a sheet of retinal cells grown from a patient’s own reprogrammed skin cells to treat macular degeneration. It was a first-in-human safety test. Since then, trials have followed for Parkinson’s disease, spinal cord injury, and heart failure. None are routine care.
Scale and limits
14. Market-size numbers for regenerative medicine are unreliable. Reports put the market anywhere from tens of billions of dollars to several times that, depending on which report you open and what it counts. Most come from market research firms, not peer-reviewed papers. The category definition is elastic, so the dollar figure moves with it.
15. Lab-grown solid organs aren’t available. More than 100,000 people are on the transplant waiting list in the United States, and that gap is a main driver of research funding. Growing a kidney, liver, or heart means building a working network of blood vessels and dozens of cell types. Researchers can make small organoids for testing drugs. They can’t yet make an organ you can transplant.
16. Chronic diseases are not cured. No approved cell therapy reverses stroke damage, heart failure, Alzheimer’s disease, ALS, or autoimmune disease. Trials continue and some show early signals, but promising results in mice and small human studies often fail to hold up at scale. Be skeptical of any source that uses the word “cure.”
Safety, cost, and red flags
17. Cells can misbehave, and unapproved clinics have caused serious harm. Possible risks include immune rejection, infection, and tumors, especially from cells that haven’t been carefully purified. In a 2017 report in the New England Journal of Medicine, three women with macular degeneration lost significant vision after a Florida clinic injected “stem cells” into their eyes. The FDA’s consumer guidance on regenerative medicine tells patients to confirm a product is approved or under an active FDA investigational application before treatment.
18. Cost is usually on you, and you can vet a clinic in about ten minutes. Insurance rarely pays for unapproved injections, so these are typically cash-pay treatments costing thousands of dollars. Before booking, check three things. Is the specific product on the FDA’s approved list? Is it part of a registered trial on ClinicalTrials.gov, where participants usually aren’t charged? Does the clinic promise to treat a long list of unrelated conditions with one injection? The International Society for Stem Cell Research runs a patient resource, A Closer Look at Stem Cells, with a checklist of warning signs. A long list of conditions and a price tag attached to a consultation are the two most common ones.
